CoChat

ACE Inhibitor???Induced Angioedema: Incidence, Prevention and Management

Vleeming, Wim, van Amsterdam, Jan G.C., Stricker, Bruno H., de Wildt, Dick J. · 1998 · Drug Safety

The DOI matches its Crossref record, with a small difference in title or year; 208 of the 210 references it cites were found in a registry or an index.

Abstract

Available information from 1980 to 1997 on angiotensin converting enzyme (ACE) inhibitor-induced angioedema and its underlying mechanisms are summarised and discussed. The incidence of angioedema is low (0.1 to 0.2%) but can be considered as a potentially life-threatening adverse effect of ACE inhibitor therapy. This adverse effect of ACE inhibitors, irrespective of the chemical structure, can occur early in treatment as well as after prolonged exposure for up to several years. The estimate incidence is quite underestimated. The actual incidence can be far higher because of poorly recognised presentation of angioedema as a consequence of its late onset in combination with usually long term therapy. Also, a spontaneous reporting bias can contribute to an actual higher incidence of this phenomenon. The incidence can be even higher (up to 3-fold) in certain risk groups, for instance Black Americans. Treatment includes immediate withdrawal of the ACE inhibitor and acute symptomatic supportive therapy followed by immediate (and long term) alternative therapy with other classes of drugs to manage hypertension and/or heart failure. Preclinical and clinical studies for the elucidation of the underlying mechanism(s) of ACE inhibitor-associated angioedema have not generated definite conclusions. It is suggested that immunological processes and several mediator systems (bradykinin, histamine, substance P and prostaglandins) are involved in the pathogenesis of angioedema. A great part of…

Overview

Integrity signals

Registry

Crossref · 10.2165/00002018-199818030-00003

Cites

208 of 208 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 208 references

Cited by

See all 247

Metadata

Authors
Vleeming, W., van Amsterdam, J. G. C., Stricker, B. H., & de Wildt, D. J.
Affiliations
  • National Institute for Public Health and the Environment (NL)
  • Erasmus University Rotterdam (NL)
Corresponding author
Vleeming, Wim
Venue
Drug Safety
Published
1998
Volume
18
Issue
3
Pages
171-188
ISSN
0114-5916 (ISSN-L)
OpenAlex
W2091790017
Cited by
243
References
210
Citations by year
2026: 2 · 2025: 5 · 2024: 6 · 2023: 3 · 2022: 7 · 2021: 4 · 2020: 6 · 2019: 6 · 2018: 8 · 2017: 6 · 2016: 8 · 2015: 13 · 2014: 8 · 2013: 14 · 2012: 8
FWCI
3.46
Type
journal article
Language
en
Open access
closed
Locations
  • Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • Rivm Repository (Netherlands National Institute for Public Health and the Environment) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
Keywords
ACE inhibitor-induced angioedema, ACE inhibitors, adverse drug reactions, bradykinin, histamine, substance P, prostaglandins, ACE gene polymorphism, pharmacogenetics, hypertension, heart failure, drug withdrawal, incidence, African Americans
MeSH terms
Angioedema, Angiotensin-Converting Enzyme Inhibitors, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ACE Inhibitor???Induced Angioedema: Incidence, Prevention and Management. https://app.cochat.ai/papers/10.2165/00002018-199818030-00003
The paper
Vleeming, W., van Amsterdam, J. G. C., Stricker, B. H., & de Wildt, D. J. (1998). ACE Inhibitor???Induced Angioedema: Incidence, Prevention and Management. Drug Safety. https://doi.org/10.2165/00002018-199818030-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.